Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Identifieur interne : 000209 ( PubMed/Curation ); précédent : 000208; suivant : 000210Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
Auteurs : Angela Yee-Moon Wang [Hong Kong] ; Fang Fang ; John Chan ; Yue-Yi Wen ; Shang Qing ; Iris Hiu-Shuen Chan ; Gladys Lo ; Kar-Neng Lai ; Wai-Kei Lo ; Christopher Wai-Kei Lam ; Cheuk-Man YuSource :
- Journal of the American Society of Nephrology : JASN ; 2014.
English descriptors
- KwdEn :
- Aged, Alkaline Phosphatase (blood), Blood Pressure (drug effects), Double-Blind Method, Echocardiography, Ergocalciferols (adverse effects), Ergocalciferols (therapeutic use), Female, Humans, Hypercalcemia (chemically induced), Hypertrophy, Left Ventricular (drug therapy), Hypertrophy, Left Ventricular (etiology), Hypertrophy, Left Ventricular (pathology), Magnetic Resonance Imaging, Male, Middle Aged, Parathyroid Hormone (blood), Prospective Studies, Renal Insufficiency, Chronic (complications), Renal Insufficiency, Chronic (drug therapy), Renal Insufficiency, Chronic (pathology), Ventricular Dysfunction, Left (drug therapy), Ventricular Dysfunction, Left (etiology), Ventricular Dysfunction, Left (physiopathology).
- MESH :
- chemical , adverse effects : Ergocalciferols.
- chemical , blood : Alkaline Phosphatase, Parathyroid Hormone.
- chemically induced : Hypercalcemia.
- complications : Renal Insufficiency, Chronic.
- drug effects : Blood Pressure.
- drug therapy : Hypertrophy, Left Ventricular, Renal Insufficiency, Chronic, Ventricular Dysfunction, Left.
- etiology : Hypertrophy, Left Ventricular, Ventricular Dysfunction, Left.
- pathology : Hypertrophy, Left Ventricular, Renal Insufficiency, Chronic.
- physiopathology : Ventricular Dysfunction, Left.
- chemical , therapeutic use : Ergocalciferols.
- Aged, Double-Blind Method, Echocardiography, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies.
Abstract
Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) or matching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolic mitral annular velocities, and ratio of early mitral inflow velocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD.
DOI: 10.1681/ASN.2013010103
PubMed: 24052631
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000209
Links to Exploration step
pubmed:24052631Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.</title><author><name sortKey="Wang, Angela Yee Moon" sort="Wang, Angela Yee Moon" uniqKey="Wang A" first="Angela Yee-Moon" last="Wang">Angela Yee-Moon Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong;</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, Queen Mary Hospital, University of Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Fang, Fang" sort="Fang, Fang" uniqKey="Fang F" first="Fang" last="Fang">Fang Fang</name></author><author><name sortKey="Chan, John" sort="Chan, John" uniqKey="Chan J" first="John" last="Chan">John Chan</name></author><author><name sortKey="Wen, Yue Yi" sort="Wen, Yue Yi" uniqKey="Wen Y" first="Yue-Yi" last="Wen">Yue-Yi Wen</name></author><author><name sortKey="Qing, Shang" sort="Qing, Shang" uniqKey="Qing S" first="Shang" last="Qing">Shang Qing</name></author><author><name sortKey="Chan, Iris Hiu Shuen" sort="Chan, Iris Hiu Shuen" uniqKey="Chan I" first="Iris Hiu-Shuen" last="Chan">Iris Hiu-Shuen Chan</name></author><author><name sortKey="Lo, Gladys" sort="Lo, Gladys" uniqKey="Lo G" first="Gladys" last="Lo">Gladys Lo</name></author><author><name sortKey="Lai, Kar Neng" sort="Lai, Kar Neng" uniqKey="Lai K" first="Kar-Neng" last="Lai">Kar-Neng Lai</name></author><author><name sortKey="Lo, Wai Kei" sort="Lo, Wai Kei" uniqKey="Lo W" first="Wai-Kei" last="Lo">Wai-Kei Lo</name></author><author><name sortKey="Lam, Christopher Wai Kei" sort="Lam, Christopher Wai Kei" uniqKey="Lam C" first="Christopher Wai-Kei" last="Lam">Christopher Wai-Kei Lam</name></author><author><name sortKey="Yu, Cheuk Man" sort="Yu, Cheuk Man" uniqKey="Yu C" first="Cheuk-Man" last="Yu">Cheuk-Man Yu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="doi">10.1681/ASN.2013010103</idno><idno type="RBID">pubmed:24052631</idno><idno type="pmid">24052631</idno><idno type="wicri:Area/PubMed/Corpus">000209</idno><idno type="wicri:Area/PubMed/Curation">000209</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.</title><author><name sortKey="Wang, Angela Yee Moon" sort="Wang, Angela Yee Moon" uniqKey="Wang A" first="Angela Yee-Moon" last="Wang">Angela Yee-Moon Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong;</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Medicine, Queen Mary Hospital, University of Hong Kong</wicri:regionArea></affiliation></author><author><name sortKey="Fang, Fang" sort="Fang, Fang" uniqKey="Fang F" first="Fang" last="Fang">Fang Fang</name></author><author><name sortKey="Chan, John" sort="Chan, John" uniqKey="Chan J" first="John" last="Chan">John Chan</name></author><author><name sortKey="Wen, Yue Yi" sort="Wen, Yue Yi" uniqKey="Wen Y" first="Yue-Yi" last="Wen">Yue-Yi Wen</name></author><author><name sortKey="Qing, Shang" sort="Qing, Shang" uniqKey="Qing S" first="Shang" last="Qing">Shang Qing</name></author><author><name sortKey="Chan, Iris Hiu Shuen" sort="Chan, Iris Hiu Shuen" uniqKey="Chan I" first="Iris Hiu-Shuen" last="Chan">Iris Hiu-Shuen Chan</name></author><author><name sortKey="Lo, Gladys" sort="Lo, Gladys" uniqKey="Lo G" first="Gladys" last="Lo">Gladys Lo</name></author><author><name sortKey="Lai, Kar Neng" sort="Lai, Kar Neng" uniqKey="Lai K" first="Kar-Neng" last="Lai">Kar-Neng Lai</name></author><author><name sortKey="Lo, Wai Kei" sort="Lo, Wai Kei" uniqKey="Lo W" first="Wai-Kei" last="Lo">Wai-Kei Lo</name></author><author><name sortKey="Lam, Christopher Wai Kei" sort="Lam, Christopher Wai Kei" uniqKey="Lam C" first="Christopher Wai-Kei" last="Lam">Christopher Wai-Kei Lam</name></author><author><name sortKey="Yu, Cheuk Man" sort="Yu, Cheuk Man" uniqKey="Yu C" first="Cheuk-Man" last="Yu">Cheuk-Man Yu</name></author></analytic><series><title level="j">Journal of the American Society of Nephrology : JASN</title><idno type="e-ISSN">1533-3450</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Alkaline Phosphatase (blood)</term><term>Blood Pressure (drug effects)</term><term>Double-Blind Method</term><term>Echocardiography</term><term>Ergocalciferols (adverse effects)</term><term>Ergocalciferols (therapeutic use)</term><term>Female</term><term>Humans</term><term>Hypercalcemia (chemically induced)</term><term>Hypertrophy, Left Ventricular (drug therapy)</term><term>Hypertrophy, Left Ventricular (etiology)</term><term>Hypertrophy, Left Ventricular (pathology)</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Parathyroid Hormone (blood)</term><term>Prospective Studies</term><term>Renal Insufficiency, Chronic (complications)</term><term>Renal Insufficiency, Chronic (drug therapy)</term><term>Renal Insufficiency, Chronic (pathology)</term><term>Ventricular Dysfunction, Left (drug therapy)</term><term>Ventricular Dysfunction, Left (etiology)</term><term>Ventricular Dysfunction, Left (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ergocalciferols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Alkaline Phosphatase</term><term>Parathyroid Hormone</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypercalcemia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blood Pressure</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertrophy, Left Ventricular</term><term>Renal Insufficiency, Chronic</term><term>Ventricular Dysfunction, Left</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hypertrophy, Left Ventricular</term><term>Ventricular Dysfunction, Left</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hypertrophy, Left Ventricular</term><term>Renal Insufficiency, Chronic</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Ventricular Dysfunction, Left</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ergocalciferols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Echocardiography</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) or matching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolic mitral annular velocities, and ratio of early mitral inflow velocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24052631</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>01</Day></DateCreated><DateCompleted><Year>2014</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-3450</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of the American Society of Nephrology : JASN</Title><ISOAbbreviation>J. Am. Soc. Nephrol.</ISOAbbreviation></Journal><ArticleTitle>Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.</ArticleTitle><Pagination><MedlinePgn>175-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2013010103</ELocationID><Abstract><AbstractText>Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) or matching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolic mitral annular velocities, and ratio of early mitral inflow velocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Angela Yee-Moon</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yue-Yi</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Qing</LastName><ForeName>Shang</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Iris Hiu-Shuen</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Gladys</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Kar-Neng</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Wai-Kei</ForeName><Initials>WK</Initials></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Christopher Wai-Kei</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Cheuk-Man</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00796679</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Nephrol</MedlineTA><NlmUniqueID>9013836</NlmUniqueID><ISSNLinking>1046-6673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004872">Ergocalciferols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C470125">PTH protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>6702D36OG5</RegistryNumber><NameOfSubstance UI="C084656">paricalcitol</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.1</RegistryNumber><NameOfSubstance UI="D000469">Alkaline Phosphatase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16810-5</RefSource><PMID Version="1">17942703</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2007 Oct;72(8):1004-13</RefSource><PMID Version="1">17687259</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2008 Jan 29;117(4):503-11</RefSource><PMID Version="1">18180395</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2008 Jul;74(2):170-9</RefSource><PMID Version="1">18385669</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Echocardiogr. 2010 Jan;11(1):51-6</RefSource><PMID Version="1">19910319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2010 Sep;31(18):2253-61</RefSource><PMID Version="1">20688781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Nephrol. 2010;32(4):296-304</RefSource><PMID Version="1">20720404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Nov 6;376(9752):1543-51</RefSource><PMID Version="1">21055801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nephrol Dial Transplant. 2011 Mar;26(3):1024-32</RefSource><PMID Version="1">20947538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Renal Physiol. 2011 Mar;300(3):F772-82</RefSource><PMID Version="1">21159735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Res. 2011 Sep 1;91(4):632-9</RefSource><PMID Version="1">21565836</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2011 Sep;58(3):374-82</RefSource><PMID Version="1">21636193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2011 Oct 25;124(17):1838-47</RefSource><PMID Version="1">21947295</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2011 Nov;80(10):1073-9</RefSource><PMID Version="1">21716260</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Clin Nutr. 2012 Jan;95(1):91-100</RefSource><PMID Version="1">22170374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2012 Feb 15;307(7):674-84</RefSource><PMID Version="1">22337679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2012 May;35(5):1158-64</RefSource><PMID Version="1">22399697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nephrol Dial Transplant. 2012 Sep;27(9):3588-94</RefSource><PMID Version="1">22523119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am Heart J. 2012 Dec;164(6):902-9.e2</RefSource><PMID Version="1">23194491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2000 Oct 10;102(15):1788-94</RefSource><PMID Version="1">11023933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hypertension. 2002 Mar 1;39(3):750-5</RefSource><PMID Version="1">11897757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2002 Jul;110(2):229-38</RefSource><PMID Version="1">12122115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2003 Apr;63(4):1483-90</RefSource><PMID Version="1">12631365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Jul 31;349(5):446-56</RefSource><PMID Version="1">12890843</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hypertension. 2003 Nov;42(5):1050-65</RefSource><PMID Version="1">14604997</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Cell Cardiol. 1986 Jan;18(1):67-72</RefSource><PMID Version="1">3005597</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1987 Jun;79(6):1706-12</RefSource><PMID Version="1">3034981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol. 1987 Dec;253(6 Pt 1):E675-83</RefSource><PMID Version="1">2827502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 1989 Aug;10(3):351-65</RefSource><PMID Version="1">2550215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 1991 Dec 16;181(2):611-6</RefSource><PMID Version="1">1661584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 1995 Jan;47(1):186-92</RefSource><PMID Version="1">7731145</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1996 Apr 1;97(7):1577-88</RefSource><PMID Version="1">8601621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Cardiol. 1997 Apr 1;79(7):921-8</RefSource><PMID Version="1">9104907</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 1997 Aug;30(2):474-80</RefSource><PMID Version="1">9247521</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 1997 Nov 15;30(6):1527-33</RefSource><PMID Version="1">9362412</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 1999 Jan;33(1):73-81</RefSource><PMID Version="1">9915270</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1999 Mar 16;130(6):461-70</RefSource><PMID Version="1">10075613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2005 Apr;16(4):1115-25</RefSource><PMID Version="1">15728786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Kidney Dis. 2005 Jun;45(6):1026-33</RefSource><PMID Version="1">15957131</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Kidney Int. 2005 Dec;68(6):2823-8</RefSource><PMID Version="1">16316359</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cardiovasc Magn Reson. 2005;7(5):775-82</RefSource><PMID Version="1">16353438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63</RefSource><PMID Version="1">16376782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2006 Mar 14;113(10):e396-8</RefSource><PMID Version="1">16534017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Nephrol. 2006;7:2</RefSource><PMID Version="1">16504054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2007 Jan;18(1):321-30</RefSource><PMID Version="1">17167121</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Jul 19;357(3):266-81</RefSource><PMID Version="1">17634462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2007 Sep 10;167(16):1730-7</RefSource><PMID Version="1">17846391</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2007 Dec 18;147(12):840-53</RefSource><PMID Version="1">18087055</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000469">Alkaline Phosphatase</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004452">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004872">Ergocalciferols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006934">Hypercalcemia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017379">Hypertrophy, Left Ventricular</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010281">Parathyroid Hormone</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D051436">Renal Insufficiency, Chronic</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018487">Ventricular Dysfunction, Left</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3871774</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">ASN.2013010103</ArticleId><ArticleId IdType="doi">10.1681/ASN.2013010103</ArticleId><ArticleId IdType="pubmed">24052631</ArticleId><ArticleId IdType="pmc">PMC3871774</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000209 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000209 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24052631
|texte= Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24052631" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |